StockTipsArenaBeta

BUY Biocon Ltd — Nandish Shah, Motilal Oswal

BUYBiocon Ltd
Biocon share price target & all analyst calls

byNandish Shah, Motilal OswalHorizon: NA (inferred 1 year)28 Oct 2026via NDTV Profit

Entry₹347.4Inferred
Target₹380
Total upside +9.38%
Stop loss₹330-5.01% risk
CMP₹351.85h ago
Active+1.27%+8.02%upside left 12 mo left
Follow Nandish Shah for new callsGet alertsWatch BIOCON for new buy/sell callsGet alertsSee 10 other Long-term calls on BIOCONSee 410 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 30 Oct, 9:22 pm IST
26 supporting10 neutral4 opposing
Supports the BUY call (26)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·30 Oct · today

Biocon gets additional global market entry for Yesintek to treat autoimmune diseases

NewsCnbc-Tv18·26 Oct · 4d ago

(opens in new tab)

Biocon settles licence agreement with Genetech for cancer treatment drug — Check earliest secured launch dates

NewsCnbc-Tv18·14 Oct · 2w ago

(opens in new tab)

1 advisor has an active short-term BUY call on this stock

Advisor consensus · adjacent horizon·19 Sept · 1mo ago

6 other SEBI-registered advisors have active long-term BUY calls on this stock

Advisor consensus · same horizon·7 Aug · 3mo ago

Neutral / worth noting (10)

Q2 FY27 results scheduled — board meets 04 Nov 2026

BSE · Board Meeting·In 4 days

(opens in new tab)
Weighs against the BUY call (4)

1 advisor has an active short-term SELL call on this stock

Advisor consensus · adjacent horizon·9 Oct · 3w ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Biocon

All analyst calls on Biocon

More from Nandish Shah, Motilal Oswal

Every call and its outcome